Building a Sustainable Pharma Ecosystem for both Brands and Generics

The continuing entry of generics and biosimilars into the Canadian market has offered significant cost savings for payers.  Ostensibly, this should free up financial resources for payers to pay for the new curative therapies coming onto the market.  This would eventually further reduce health care expenditures overall, creating a virtuous circle that benefits all stakeholders.  It’s a great theory, but is it actually happening?  Take back to your team a blueprint to:

• Assess how the market has responded since biosimilars were mandated for public payers and adopted across Canada
• Analyse the lifecycle of your portfolio to determine when pursuing secondary patenting makes sense and when it doesn’t
• Understand how public payers can harness health economic research to justify greater expenditures on new, curative therapies, and what internal budgetary hurdles must be overcome
• Use the economic benefits that generics and biosimilars bring to the healthcare system to promote a more collaborative approach to drug development in Canada

Learn where opportunities will emerge when Brands and Generics co-exist in a stable, balanced marketplace.